Therapeutic Response

ER positive, ESR1 activating variants, and HER2-negative status confers therapeutic sensitivity to Vepdegestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description

Veppanu (vepdegestrant) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to vepdegestrant for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.